Denali Therapeutics Inc.
A biotech company building medicines that can actually reach the brain to fight diseases like Alzheimer's and Parkinson's. Its signature "Transport Vehicle" technology rides drugs across the blood-brain barrier, the natural shield that keeps most treatments out. Three former Genentech scientists founded Denali in 2015, naming it after North America's tallest peak—the Athabascan word for "the high one"—to signal their ambition to conquer the hardest medical challenges.
Granted 12.8K
Granted 79.0K · Sold 35.2K
Granted 6.4K
Granted 57.7K · Sold 17.2K
Granted 6.4K
Granted 6.4K
Granted 6.4K
Granted 6.4K
Granted 6.4K
Granted 17.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP +5 co-filersDirector · 2 transactions | — | 10.57M | 12.8K | — | — |
| Watts Ryan J.President and CEO, Director · 3 transactions | -15.9% | 2.45M | 79.0K | — | 35.2K |
| Krognes Steve E.Director · 1 transaction | +0.8% | 820.0K | 6.4K | — | — |
| Schuth Alexander O.COFO and Secretary · 2 transactions | +5.3% | 806.6K | 57.7K | — | 17.2K |
| Flatley Jay TDirector · 1 transaction | +1.8% | 358.9K | 6.4K | — | — |
| Schenkein David PDirector · 1 transaction | +8.8% | 79.1K | 6.4K | — | — |
| Klein Peter SDirector · 1 transaction | +23.3% | 33.9K | 6.4K | — | — |
| Cook Jennifer E.Director · 1 transaction | +24.6% | 32.5K | 6.4K | — | — |
| Thornberry NancyDirector · 1 transaction | +25.9% | 31.1K | 6.4K | — | — |
| Van Hauwermeiren TimothyDirector · 2 transactions | — | 17.0K | 17.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -52.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.